Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLERANCE HCC: Cabozantinib Tolerance Study
NCT03963206Phase 4Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Hospices Civils de Lyon. Started Sep 2019; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03963206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03963206.